DESCRIPTION

• Notes: License Disclosure: Visit bpsbioscience.com/license for the label license and other key information about this product.  Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
• Genbank: QHD43416.1
• Species: Replication Incompetent HIV
• Uniprot: P0DTC2
• Mutation: Y145del, H146del, E484K, D614G
• Shiptemp: -80°C (dry ice)
• Synonyms: coronavirus, covid, covid-19, covid19, Sars-cov-2, India variant, sars cov 2, sarscov2, B1618 lenti, India mutation, India lentivirus, pseudovirus, pseudovirion, Luc reporter, 78206-1, 78206-2
• Warnings: Avoid repeated freeze/thaw cycles. Titers can drop significantly with each freeze/thaw cycle. Biosafety None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions.
• Category: Coronavirus/Lentivirus
• Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. A variant called B.1.618 was identified in India in the spring of 2021. This variant has a number of mutations that allow the virus to spread more easily and quickly than other variants.   The Spike (B.1.618 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.618 Variant Spike (Genbank Accession #QHD43416.1 with B.1.618 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (B.1.618 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.618 variant in a Biosafety Level 2 facility.   Spike Mutations in B.1.618 Variant: Y145del H146del E484K D614G
• Formulation: The lentiviruses were produced from HEK293T cells. Supplied in medium containing 90% DMEM + 10% FBS. Media Formulation Thaw Medium 1 (BPS Bioscience #60187): MEM medium (Hyclone, #SH30024.01) supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na pyruvate, 1% Penicillin/Streptomycin (Hyclone, #SV30010.01).
• Supplied As: The titer will vary with each lot; the exact value is provided with each shipment.
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Product Type: Lentivirus
• Biosafety Level: BSL-2
• Related Products: 60690, 60187, 79951, 101024
• Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
• Scientific Category: Coronavirus
• Instructions for Use: See assay protocol for detailed instructions